Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huzhangxiefei Decoction is a Traditional Chinese Medicine (TCM) herbal formula being investigated for the treatment of sepsis-induced acute lung injury (ALI). Developed by researchers at Xinhua Hospital, affiliated with the Shanghai Jiao Tong University School of Medicine, the decoction is administered orally or via nasogastric tube. It is hypothesized to attenuate systemic organ failure and lung injury by modulating inflammatory biomarkers (such as C-reactive protein and procalcitonin), reducing vascular and alveolar epithelial injury, and promoting a fibrinolytic state. The formula likely contains *Polygonum cuspidatum* (Huzhang) as a primary ingredient, which is known for its anti-inflammatory and antioxidant properties. Clinical evaluation focuses on its ability to improve respiratory rates, oxygenation indices, and chest X-ray scores in patients with sepsis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huzhangxiefei decoction (Xinhua Hospital).